secwatch / observer
8-K filed June 12, 2026, 4:10 PM ET ticker OPRX CIK 0001448431
other material confidence high sentiment neutral materiality 0.40

OptimizeRx shareholders OK 1M-share equity plan increase; reject evergreen auto-increase

OptimizeRx Corp

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OptimizeRx Corp shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
5. Grant Thornton LLP was ratified as the Company’s independent registered public accounting firm for the 2026 fiscal year based upon the following votes: Votes in Favor Votes Against Abstain 15,750,329 27,585 14,338
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OptimizeRx Corp shareholders rejected Amendment to Equity Plan to adopt an evergreen provision for automatic annual increase in shares at the 2026-06-09 meeting.

Proposal
equity plan
Outcome
failed
Meeting
2026-06-09
Exact text from the filing
4. The amendment to the Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the Equity Plan was not approved based upon the following votes: Votes in Favor Votes Against Abstain Broker Non-Votes 5,627,324 7,001,699 24,773 3,138,456
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OptimizeRx Corp shareholders approved Election of seven directors to serve until next annual meeting at the 2026-06-09 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
1. The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Lynn O’Connor Vos 8,327,850 4,325,946 3,138,456 Catherine Klema 9,079,088 3,574,708 3,138,456 James Lang 10,329,173 2,324,623 3,138,456 Patrick Spangler 8,092,151 4,561,645 3,138,456 Mariyamma Varghese Presti 11,766,568 887,228 3,138,456 Gregory Wasson 10,324,948 2,328,848 3,138,456 Stephen Silvestro 12,160,558 493,238 3,138,456 1
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OptimizeRx Corp shareholders approved Amendment to Equity Plan to increase aggregate number of shares by 1,000,000 at the 2026-06-09 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
3. The amendment to the Equity Plan to increase the aggregate number of shares of Common Stock available for awards under the Equity Plan by 1,000,000 shares was approved based upon the following votes: Votes in Favor Votes Against Abstain Broker Non-Votes 11,541,123 1,096,197 16,476 3,138,456
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

OptimizeRx Corp shareholders approved Advisory approval of named executive officer compensation at the 2026-06-09 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-09
Exact text from the filing
2. The compensation of the Company’s named executive officers, as described in the proxy statement, was approved on an advisory basis based upon the following votes: Votes in Favor Votes Against Abstain Broker Non-Votes 11,660,549 895,095 98,152 3,138,456
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

OptimizeRx Corp filing history →

Source: SEC EDGAR
accession 0001213900-26-068272
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.